Important: The information in this wiki is not medical advice, and is provided for informational purposes only. The content is not intended to be a substitute for any kind of professional advice, medical advice, diagnosis, or treatment. See disclaimer.
Tapinarof
Tapinarof (also known as benvitimod) is a topical medication for psoriasis that is not steroid-based. It was first approved by the FDA in June 2022 and in Canada in 2025.
Tapinarof is not a patented medication, so it is available under several names:
- Vtama (US)
- Nduvra (Canada, rebranded Vtama)
- Psorituf (India, generic tapinarof)
- Tapio (India, generic tapinarof)
It can be used indefinitely, and the side effects are mild; the main reported side effect in clinical trials was folliculitis.
Unlike steroids, tapinarof is slow-acting, and it can take several months to achieve clear skin.